- Room N13, ITTC Building, Plymouth Science Park, Davy Road, PL6 8BX
- +44 1752 430055
- jeremy.hobart@plymouth.ac.uk
Profiles
Professor Jeremy Hobart
Professor
Peninsula Medical School (Faculty of Health)
Professor Jeremy Hobart can be contacted through arrangement with our Press Office, to speak to the media on these areas of expertise.
- Clinical trials
- Psychometrics
- Rating scale science
- Health outcomes
- Health measurement
- Multiple Sclerosis diagnosis
- Multiples Sclerosis management
- Clinical neurology
Email publicrelations@plymouth.ac.uk to enquire.
Biography
Biography
- Consultant Neurologist Plymouth Hospitals NHS Trust
- Professor of Clinical Neurology and Health Measurement Plymouth University Peninsula Schools of Medicine and Dentistry
Qualifications
Jeremy Hobart BSc PhD FRCP Dip Public Health
Dr Jeremy Hobart is a Consultant Neurologist at Derriford Hospital, and Professor at the Plymouth University Peninsula Schools of Medicine and Dentistry. His clinical sub-specialist interest is the diagnosis and management of people with multiple sclerosis. His medical training was at St Mary’s Hospital Medical School in London, and neurology training was undertaken predominantly at the National Hospital for Neurology and Neurosurgery, Queen Square. He is also President of the South Devon branch of the MS Society.
Jeremy Hobart’s research interest is rating scales for measuring health outcomes. His training in health measurement and rating scale science has included a PhD in Psychometrics from the London School of Hygiene and Tropical Medicine (Prof Donna Lamping), and post doctoral attachments to the University of Chicago (Prof Ben Wright) and, more recently, a secondment to Murdoch University Perth, Western Australia (Prof David Andrich) sponsored by a Royal Society of Medicine Ellison-Cliffe Travelling Fellowship.
By a combination of chance and design, this training means that Jeremy is one of only a handful of clinicians formally trained in rating scale science. He has led the development of a number of rating scales, has published widely in this area, and holds over £7 million in research grants.
Jeremy Hobart is a Consultant Neurologist at Plymouth Hospitals NHS Trust, and Professor in Clinical Neurology and Health Measurement at the Plymouth University Peninsula Schools of Medicine and Dentistry.
Key publications
(2009) 'Friedreich's ataxia impact scale: a new measure striving to provide the flexibility required by today's studies' Mov Disord 24, (7) 984-992 , DOI
(2009) 'Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods' Health Technol Assess 13, (12) iii-177 , DOI
(2011) 'Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis' Nature 476, (7359) 214-219 , DOI Open access
(2010) 'The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts' J Neurol Neurosurg Psychiatry 81, (12) 1363-1368 , DOI
(2010) 'Effect sizes can be misleading: is it time to change the way we measure change?' J Neurol Neurosurg Psychiatry 81, (9) 1044-1048 , DOI
Publications
Publications
Key publications
(2009) 'Friedreich's ataxia impact scale: a new measure striving to provide the flexibility required by today's studies' Mov Disord 24, (7) 984-992 , DOI
(2009) 'Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods' Health Technol Assess 13, (12) iii-177 , DOI
(2011) 'Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis' Nature 476, (7359) 214-219 , DOI Open access
(2010) 'The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts' J Neurol Neurosurg Psychiatry 81, (12) 1363-1368 , DOI
(2010) 'Effect sizes can be misleading: is it time to change the way we measure change?' J Neurol Neurosurg Psychiatry 81, (9) 1044-1048 , DOI
Key publications are highlighted
Journals
Articles
(2023) 'Measuring Health and Well-Being: We Need to Get it Right for Patients, With Patients' Value in Health 26, (3) 435-437 , DOI
(2022) 'Timely intervention, monitoring and education MATTERS in MS (TIME MATTERS in MS): Development of a globally applicable quality improvement tool' Multiple Sclerosis Journal - Experimental, Translational and Clinical 8, (3) , DOI Open access
(2022) 'Patient-reported outcome measures in MS: Do development processes and patient involvement support valid quantification of clinically important variables?' Multiple Sclerosis Journal - Experimental, Translational and Clinical 8, (2) 205521732211056-205521732211056 , DOI Open access
(2022) 'Evaluating the feasibility of a real world pharmacovigilance study (OPTIMISE:MS)' Multiple Sclerosis and Related Disorders 63, , DOI Open access
(2022) 'Efficacy of prolonged-release fampridine versus placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCE' Therapeutic Advances in Neurological Disorders , DOI Open access
(2022) 'The agenda of the global patient reported outcomes for multiple sclerosis (PROMS) initiative: Progresses and open questions' Multiple Sclerosis and Related Disorders 61, 103757-103757 , DOI
(2022) 'Factors Associated With Relapse and Treatment of Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease in the United Kingdom' JAMA Network Open 5, (1) , DOI Open access
(2022) 'Factors contributing to CSF NfL reduction over time in those starting treatment for multiple sclerosis: An observational study' Multiple Sclerosis and Related Disorders 57, 103409-103409 , DOI
(2022) 'Efficacy of prolonged-release fampridine <i>versus</i> placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCE' Therapeutic Advances in Neurological Disorders 15, , DOI Open access
(2021) 'OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosis' BMJ Open 11, (11) , DOI Open access
(2021) 'The impact of smoking cessation on multiple sclerosis disease progression' Brain , DOI Open access
(2021) 'Hyperhidrosis Disease Severity Measure-Axillary (HDSM-Ax): Evaluation of Measurement Performance' Journal of drugs in dermatology : JDD , DOI Open access
(2021) 'Subcutaneous cladribine to treat multiple sclerosis: experience in 208 patients' Therapeutic Advances in Neurological Disorders 14, , DOI Open access
(2020) 'Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study' CNS Drugs , DOI Open access
(2020) 'State of the Art and Future Challenges in Multiple Sclerosis Research and Medical Management: An Insight into the 5th International Porto Congress of Multiple Sclerosis' Neurology and Therapy , DOI Open access
(2020) 'Cognition and its relation to brain health in patients with MS: Response to letter' Multiple Sclerosis Journal 26, (12) 1613-1614 , DOI Open access
(2020) 'Clinical features and genetic risk of demyelination following anti-TNF treatment' Journal of Crohn's and Colitis , DOI Open access
(2020) 'Measuring upper limb function in MS: Which existing patient reported outcomes are fit for purpose?' eNeurologicalSci 19, 100237-100237 , DOI Open access
(2020) 'Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial' The Lancet Neurology 19, (3) 214-225 , DOI Open access
(2018) 'Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-blind, Phase III ENHANCE Trial of Prolonged-release Fampridine' CNS Drugs 33, (1) 61-79 , DOI Open access
(2018) 'International consensus on quality standards for brain health-focused care in multiple sclerosis' Multiple Sclerosis Journal , DOI Open access
(2018) 'International consensus on quality standards for brain health-focused care in multiple sclerosis' Multiple Sclerosis 1352458518809326-1352458518809326 , DOI Open access
(2018) 'Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience – report of an expert meeting' Therapeutic Advances in Neurological Disorders , DOI Open access
(2018) 'The Hyperhidrosis Disease Severity Measure-Axillary: Conceptualization and Development of Item Content' Journal of Drugs in Dermatology Open access
(2018) 'Validating the portal population of the United Kingdom Multiple Sclerosis Register' Multiple Sclerosis and Related Disorders 24, 3-10 , DOI
(2018) 'Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension' The Lancet Neurology 17, (5) 405-415 , DOI
(2017) 'Testing patient-reported outcome measurement equivalence in multinational clinical trials: An exemplar using the 12-item Multiple Sclerosis Walking Scale' Multiple Sclerosis Journal - Experimental, Translational and Clinical 3, (3) , DOI Open access
(2017) 'Clinician-Reported Outcome Assessments of Treatment Benefit: Report of the ISPOR Clinical Outcome Assessment Emerging Good Practices Task Force' Value in Health 20, (1) 2-14 , DOI
(2016) 'Measuring treatment satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication fit for purpose?' Multiple Sclerosis Journal 23, (4) 604-613 , DOI Open access
(2016) 'Brain health: time matters in multiple sclerosis' Multiple Sclerosis and Related Disorders 9, S5-S48 , DOI Open access
(2016) 'An investigation of commonly prescribed stretches of the ankle plantarflexors in people with Multiple Sclerosis' Clinical Biomechanics 37, 22-26 , DOI Open access
(2016) 'Measuring spinal surgical success: the proportion achieving acceptable symptoms' The Spine Journal 16, (4) S19-S20 , DOI Open access
(2015) 'Measuring the Impact of Multiple Sclerosis: Enhancing the Performance of the Msis-29 and Msws-12' Value in Health 18, (7) A709-A710 , DOI
(2015) 'Measuring the Impact of Secondary Progressive Multiple Sclerosis (Spms) in the Ascend Trial: Equating the Msis-29, Msws-12, Abilhand-56 and Sf-36' Value in Health 18, (7) A713-A713 , DOI
(2015) 'Clinical Outcome Assessments: Conceptual Foundation—Report of the ISPOR Clinical Outcomes Assessment – Emerging Good Practices for Outcomes Research Task Force' Value in Health 18, (6) 741-752 , DOI
(2015) 'Identifying an important change estimate for the Multiple Sclerosis Walking Scale-12 (MSWS-12v1) for interpreting clinical trial results' Multiple Sclerosis Journal - Experimental, Translational and Clinical 1, 205521731559699-205521731559699 , DOI
(2015) 'Measuring arm function early after stroke: is the DASH good enough?' Journal of Neurology, Neurosurgery & Psychiatry 87, (6) 604-610 , DOI Open access
(2015) 'People receiving unnecessary treatments: accurate diagnosis is key' BMJ 350, (jun02 26) h2962-h2962 , DOI
(2015) 'Identifying a Minimally Important Change Threshold for The Multiple Sclerosis Walking Scale-12 (MSWS-12)' MULTIPLE SCLEROSIS JOURNAL 21, (6) 813-814 Open access
(2015) 'Measuring Upper Limb Function In Multiple Sclerosis: Enhancing The Abilhand’s Performance' Value in Health 18, (3) A24-A24 , DOI
(2015) 'Lending a hand: can DASH items help ABILHAND improve manual ability measurement in multiple sclerosis?' Mult Scler 21, (5) 612-621 , DOI
(2015) 'Definitions, diagnosis, and decompression in spinal surgery: problems and solution' Spine J 15, (3 Suppl) S5-S8 , DOI
(2015) 'The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis' Health Technol Assess 19, (12) vii-187 , DOI
(2014) 'Is NICE guidance for identifying lumbar nerve root compression misguided?' Eur Spine J 23 Suppl 1, (Suppl 1) S20-S24 , DOI
(2013) 'Achieving valid patient-reported outcomes measurement: a lesson from fatigue in multiple sclerosis' Mult Scler 19, (13) 1773-1783 , DOI Open access
(2013) 'Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis' NATURE GENETICS 45, (11) 1353-+ , DOI
(2013) 'Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial' Lancet Neurology 2013, 1-9 , DOI
(2013) 'A “Candidate-Interactome” Aggregate Analysis of Genome-Wide Association Data in Multiple Sclerosis' PLoS ONE 8, (5) e63300-e63300 , DOI Open access
(2013) 'Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MS' Neurology 80, (16) 1509-1517 , DOI
(2013) 'Evaluating change in mobility in people with multiple sclerosis: relative responsiveness of four clinical measures' Multiple Sclerosis Journal 1-8 , DOI
(2013) 'Evaluating change in mobility in people with multiple sclerosis: relative responsiveness of four clinical measures' Mult Scler 19, (12) 1632-1639 , DOI
(2013) 'Interspinous spacers for lumbar foraminal stenosis: formal trials are justified' Eur Spine J 22 Suppl 1, (Suppl 1) S47-S53 , DOI
(2013) 'Putting the Alzheimer's cognitive test to the test I: traditional psychometric methods' Alzheimers Dement 9, (1 Suppl) S4-S9 , DOI
(2013) 'Putting the Alzheimer's cognitive test to the test II: Rasch Measurement Theory' Alzheimers Dement 9, (1 Suppl) S10-S20 , DOI
(2013) 'Establishing the psychometric underpinning of cognition measures for clinical trials of Alzheimer's disease and its precursors: A new approach' Alzheimer's & Dementia 9, (1S) , DOI
(2012) 'What sample sizes for reliability and validity studies in neurology?' J Neurol 259, (12) 2681-2694 , DOI
(2012) 'Multiple sclerosis and extract of cannabis: results of the MUSEC trial' J Neurol Neurosurg Psychiatry 83, (11) 1125-1132 , DOI
(2012) 'Multiple Sclerosis and Extract of Cannabis (MUSEC) – a randomised, double-blind, placebo-controlled phase III trial to determine the efficacy and safety of a standardised oral extract of Cannabis sativa for the symptomatic relief of muscle stiffness and pain in multiple sclerosis' Journal of Neurology, Neurosurgery and Psychiatry 83, 1125-1132 Publisher Site , DOI
(2012) 'Psychometric performance of a generic walking scale (Walk-12G) in multiple sclerosis and Parkinson's disease' JOURNAL OF NEUROLOGY 259, (4) 729-738 , DOI
(2012) '125 Campath-1H for multiple sclerosis: a pain in the neck?' Journal of Neurology, Neurosurgery & Psychiatry 83, (3) e1.76-e1 , DOI
(2011) 'Multiple Sclerosis Walking Scale (MSWS-12): changes on all items are not equal' MULTIPLE SCLEROSIS JOURNAL 17, S92-S93
(2011) 'Multiple Sclerosis Walking Scale (MSWS-12): exactly what clinical benefits do prolonged-release fampridine responders actually get?' MULTIPLE SCLEROSIS JOURNAL 17, S319-S320
(2011) 'Responses to items of the MSWS-12 differ depending on EDSS and the impact of prolonged-release fampridine on walking speed' MULTIPLE SCLEROSIS JOURNAL 17, S473-S474
(2011) 'A tool to measure the attributes of receiving IV therapy in a home versus hospital setting: the Multiple Sclerosis Relapse Management Scale (MSRMS)' Health Qual Life Outcomes 9, , DOI Open access
(2011) 'Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis' Nature 476, (7359) 214-219 , DOI Open access
(2011) 'Beyond the reach of traditional analyses: using Rasch to evaluate the DASH in people with multiple sclerosis' Mult Scler 17, (2) 214-222 , DOI
(2010) 'The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts' J Neurol Neurosurg Psychiatry 81, (12) 1363-1368 , DOI
(2010) 'Patient-orientated longitudinal study of multiple sclerosis in south west England (The South West Impact of Multiple Sclerosis Project, SWIMS) 1: protocol and baseline characteristics of cohort' BMC Neurol 10, , DOI Open access
(2010) 'Cross-cultural Comparisons: Lessons from Friedreich's Ataxia' QUALITY OF LIFE RESEARCH 19, 64-65
(2010) 'Does a Rasch-modified FSS deliver better measurements?' QUALITY OF LIFE RESEARCH 19, 89-89
(2010) 'Effect sizes can be misleading: Is it time to change the way we measure change?' QUALITY OF LIFE RESEARCH 19, 41-41
(2010) 'Validity in fatigue measurement: complementing quality and quantity' QUALITY OF LIFE RESEARCH 19, 14-14
(2010) 'Effect sizes can be misleading: is it time to change the way we measure change?' J Neurol Neurosurg Psychiatry 81, (9) 1044-1048 , DOI
(2010) 'Modafinil for multiple sclerosis fatigue: Does it work?' CLINICAL NEUROLOGY AND NEUROSURGERY 112, (1) 29-31 , DOI
(2009) 'LINGUISTIC VALIDATION OF THE MULTIPLE SCLEROSIS IMPACT SCALE (MSIS-29) FOR USE IN 29 LANGUAGES' VALUE IN HEALTH 12, (7) A371-A371 , DOI
(2009) 'O4‐04‐07: The ADAS‐cog's performance as a measure—lessons from the ADNI study: Part 2 ‐ evaluation using modern psychometric methods' Alzheimer's & Dementia 5, (4S_Part_5) , DOI
(2009) 'P1‐269: The ADAS‐cog's performance as a measure ‐ lessons from the ADNI study: Part 1 ‐ evaluation using traditional psychometric methods' Alzheimer's & Dementia 5, (4S_Part_9) , DOI
(2009) 'P1‐270: The ADAS‐cog's performance as a measure ‐ lessons from the ADNI study: Part 3 ‐ do the scale modifications add value?' Alzheimer's & Dementia 5, (4S_Part_9) , DOI
(2009) 'Friedreich's ataxia impact scale: a new measure striving to provide the flexibility required by today's studies' Mov Disord 24, (7) 984-992 , DOI
(2009) 'The size of the treatment effect: do patients and proxies agree?' BMC NEUROLOGY 9, , DOI Open access
(2009) 'The ADAS-cog's Performance as a Measure- Lessons from the ADNI study. Part 1 Evaluation using traditional Psychometric Methods AAN' Neurology (72)
(2009) 'Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods' Health Technol Assess 13, (12) iii-177 , DOI
(2008) 'The cervical dystonia impact profile (CDIP-58): can a Rasch developed patient reported outcome measure satisfy traditional psychometric criteria?' Health Qual Life Outcomes 6, , DOI Open access
(2008) 'Taking a lead against evil - Response' PSYCHOLOGIST 21, (2) 169-169
(2008) 'Item response' Psychologist 21, (2)
(2008) 'Rating scales for clinical studies in neurology: challenges and opportunities' US Neurology 4, (1)
(2007) 'Measuring health-related quality of life in MSA: the MSA-QoL' Mov Disord 22, (16) 2332-2338 , DOI
(2007) 'Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations' Lancet Neurol 6, (12) 1094-1105 , DOI
(2007) 'Exploring the relationships between provision of welfare benefits advice and the health of elderly people: a longitudinal observational study and discussion of methodological issues' Health Soc Care Community 15, (5) 454-463 , DOI
(2007) 'Quantifying the impact of dyskinesias in PD: the PDYS-26: a patient-based outcome measure' Neurology 69, (6) 555-563 , DOI
(2007) 'Measuring outcomes in clinical trials of stroke: time for state-of-the-art clinical trials to reject state-of-the-ark rating scales' JOURNAL OF NEUROLOGY 254, (8) 1119-1119 , DOI
(2007) 'Beware all neurologists: The FDA's tough new requirements for rating scale performance are coming to a study near you soon' Journal of Neurology Neurosurgery and Psychiatry 78, (9)
(2007) 'Evidence-based guidelines for using the short form 36 in cervical dystonia' Movement Disorders 22, (1) 122-126
(2007) 'Exploring the relationships between provision of welfare benefits advice and the health of elderly people: a longitudinal observational study and discussion of methodological issues' Health & Social Care in the Community 15, (5) 454-463
(2007) 'Measuring health-related quality of life in MSA: The MSA-QoL' Movement Disorders 22, (16) 2332-2338
(2007) 'Measuring with rating scales - principles of measurements' Multiple Sclerosis 13, S15-S15
(2007) 'Proxy measurements in MS: does patient's cognitive impairment influence patient-proxy agreement on disease impact?' Multiple Sclerosis 13, S213-S213
(2007) 'Quantifying the impact of dyskinesias in PD - The PDYS-26: A patient-based outcome measure' Neurology 69, (6) 555-563
(2007) 'Evidence-based guidelines for using the Short Form 36 in cervical dystonia' Mov Disord 22, (1) 122-126 , DOI
(2007) 'Rating scale responsiveness: Its time to change the way we measure change' Journal of Neurology Neurosurgery and Psychiatry 78, (9)
(2007) 'Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations' Lancet Neurology 6, (12) 1094-1105
(2007) 'Sample size calculations for evaluating neurological rating scales: How many is enough?' Journal of Neurology Neurosurgery and Psychiatry 78, (9)
(2007) 'Selecting the right rating scale: Do neurologists have to have what they're given or can they get what they need?' Journal of Neurology Neurosurgery and Psychiatry 78, (9)
(2006) 'CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia' Neurology 67, (12) 2230-2232 , DOI
(2006) 'Exploring disability rating scale responsiveness II: do more response options help?' Neurology 67, (11) 2056-2059 , DOI
(2006) 'Talking the talk on walking the walk: a 12-item generic walking scale suitable for neurological conditions?' J Neurol 253, (12) 1594-1602 , DOI
(2006) 'Measuring outcomes in cervical spine surgery: think twice before using the SF-36' Spine (Phila Pa 1976) 31, (22) 2575-2584 , DOI
(2006) 'Proxy measurements in multiple sclerosis: agreement between patients and their partners on the impact of multiple sclerosis in daily life' JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY 77, (10) 1157-1162 , DOI
(2006) 'Coordinating outcomes measurement in ataxia research: do some widely used generic rating scales tick the boxes?' Mov Disord 21, (9) 1396-1403 , DOI
(2006) 'Home versus outpatient administration of intravenous steroids for multiple-sclerosis relapses: a randomized controlled trial' American Journal of Ophthalmology 142, (3) 535-535 , DOI
(2006) 'Treating multiple sclerosis relapses at home or in hospital out-patients: a randomised controlled trial of intravenous steroid delivery' Lancet Neurology 7, (5) 565-571
(2006) 'Home versus outpatient administration of intravenous steroids for multiple-sclerosis relapses: a randomised controlled trial' The Lancet Neurology 5, (7) 565-571 , DOI
(2006) 'CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia' Neurology 67, (12) 2230-2232
(2006) 'Coordinating outcomes measurement in ataxia research: Do some widely used generic rating scales tick the boxes?' Movement Disorders 21, (9) 1396-1403
(2006) 'Does the GHQ-30 leave room for change?' Journal of Neurology Neurosurgery and Psychiatry 77, (1)
(2006) 'Exploring disability rating scale responsiveness II: Do more response options help?' Neurology 67, (11) 2056-2059
(2006) 'Getting the measure of spasticity in MS: The Multiple Sclerosis Spasticity Scale (MSSS-88)' Journal of Neurology Neurosurgery and Psychiatry 77, (1)
(2006) 'Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88)' Brain 129, 224-234
(2006) 'Home versus outpatient administration of intravenous steroids for multiple-sclerosis relapses: a randomised controlled trial' Lancet Neurology 5, (7) 565-571
(2006) 'International co-operative ataxia rating scale (ICARS): Suitable for clinical practice and treatment trials in Friedreich's ataxia?' Journal of Neurology Neurosurgery and Psychiatry 77, (1)
(2006) 'Introducing the south west impact of multiple sclerosis (SWIMS) project: A population-based natural history project to acquire patient-orientated information about the impact of multiple sclerosis' Journal of Neurology Neurosurgery and Psychiatry 77, (1)
(2006) 'Is it Rasch to compare thee on another scale?' Journal of Neurology Neurosurgery and Psychiatry 77, (1)
(2006) 'Laughing all the way to the item bank: How to improve your treatment effect by improving your outcome measurement' Journal of Neurology Neurosurgery and Psychiatry 77, (1)
(2006) 'Meaningless statistics and the illusion of fatigue' Journal of Neurology Neurosurgery and Psychiatry 77, (1)
(2006) 'Measuring outcomes in cervical spine surgery: Think twice before using the SF-36' Spine 31, (22) 2575-2584
(2006) 'Measuring quality of life in PSP - The PSP-QoL' Neurology 67, (1) 39-44
(2006) 'Proxy measurements in multiple sclerosis: agreement between patients and their partners on the impact of multiple sclerosis in daily life' Journal of Neurology Neurosurgery and Psychiatry 77, (10) 1157-1162
(2006) 'Rating scales for neurological diseases: Lessons from Rasch analysis' Journal of Neurology Neurosurgery and Psychiatry 77, (1)
(2006) 'The Friedreich's Ataxia impact scale (FAIS) meets the needs of today's clinical studies' Journal of Neurology Neurosurgery and Psychiatry 77, (1)
(2006) 'The multiple sclerosis impact scale is sensitive to factors predictive of increasing severity of multiple sclerosis' Multiple Sclerosis 12, S87-S87
(2006) 'Talking the talk on walking the walk - A 12-item generic walking scale suitable for neurological conditions?' Journal of Neurology 253, (12) 1594-1602
(2005) 'How severe is chronic pain in multiple sclerosis?' NATURE CLINICAL PRACTICE NEUROLOGY 1, (2) 80-81 , DOI
(2005) 'International Cooperative Ataxia Rating Scale (ICARS): appropriate for studies of Friedreich's ataxia?' Mov Disord 20, (12) 1585-1591 , DOI
(2005) 'Measuring quality of life in multiple sclerosis: not as simple as it sounds' MULTIPLE SCLEROSIS JOURNAL 11, (6) 708-712 , DOI
(2005) 'Getting the measure of spasticity in Multiple Sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS - 89)' Brain 129, (1) 224-234 , DOI
(2005) 'Measuring health-related quality of life in patients with progressive supranuclear palsy' Neurocase 11, (4) 246-249 , DOI
(2005) 'Evaluating neurorehabilitation: lessons from routine data collection' J Neurol Neurosurg Psychiatry 76, (5) 723-728 , DOI
(2005) 'Confounding the confused: is measuring the frequency and severity of cognitive impairment really necessary?' Multiple Sclerosis 11, S68-S68
(2005) 'Confounding the confused: Is measuring the frequency and severity of cognitive impairment really necessary?' Journal of the Neurological Sciences 238, S220-S220
(2005) 'Developing rating scales for multiple sclerosis: lessons from Rasch analysis' Multiple Sclerosis 11, S104-S104
(2005) 'Developing rating scales for neurological diseases: Lessons from Rasch analysis' Journal of the Neurological Sciences 238, S229-S230
(2005) 'Evaluating neurorehabilitation: lessons from routine data collection' Journal of Neurology Neurosurgery and Psychiatry 76, (5) 723-728
(2005) 'Getting the measure of spasticity in MS: the multiple sclerosis spasticity scale' Multiple Sclerosis 11, S104-S104
(2005) 'Getting the measure of spasticity in MS: The Multiple Sclerosis Spasticity Scale (MSSS-88)' Journal of the Neurological Sciences 238, S229-S229
(2005) 'Home or away? A randomised controlled trial of treating acute multiple sclerosis relapses with intravenous steroids' Multiple Sclerosis 11, S181-S181
(2005) 'How responsive is the Multiple Sclerosis Impact Scale (MSIS-29)? A comparison with some other self report scales' Journal of Neurology Neurosurgery and Psychiatry 76, (11) 1539-1543
(2005) 'How responsive is the Multiple Sclerosis Impact Scale (MSIS-29)? A comparison with some other self report scales' Journal of Neurology, Neurosurgery and Psychiatry 76, (11) 1539-1543 , DOI
(2005) 'How severe is chronic pain in multiple sclerosis?' Nature Clinical Practice Neurology 1, (2) 80-81
(2005) 'International Cooperative Ataxia Rating Scale (ICARS): Appropriate for studies of Friedreich's ataxia?' Movement Disorders 20, (12) 1585-1591
(2005) 'Introducing the South West Impact of Multiple Sclerosis Project: a patient-focused natural history study of multiple sclerosis' Multiple Sclerosis 11, S110-S110
(2005) 'Is it Rasch to compare thee on another scale?' Multiple Sclerosis 11, S104-S104
(2005) 'Is it Rasch to compare thee on another scale?' Journal of the Neurological Sciences 238, S221-S221
(2005) 'Laughing all the way to the item bank: how to improve your treatment effect by improving your outcome measurement' Journal of the Neurological Sciences 238, S220-S221
(2005) 'Meaningless statistics and the illusion of fatigue measurement' Multiple Sclerosis 11, S68-S68
(2005) 'Measuring health-related quality of life in patients with progressive supranuclear palsy' Neurocase 11, (4) 246-249
(2005) 'Measuring quality of life in multiple sclerosis: not as simple as it sounds' Multiple Sclerosis 11, (6) 708-712
(2004) 'Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study' Neurology 63, (7) 1245-1250 , DOI
(2004) 'Patient-based outcomes of cervical dystonia: a review of rating scales' Mov Disord 19, (9) 1054-1059 , DOI
(2004) 'Exploring rating scale responsiveness: does the total score reflect the sum of its parts?' Neurology 62, (10) 1842-1844 , DOI
(2004) 'Stroke in Devon: knowledge was good, but action was poor' J Neurol Neurosurg Psychiatry 75, (4) 567-571 , DOI Open access
(2004) 'Improving the evaluation of therapeutic interventions in multiple sclerosis: development of a patient-based measure of outcome' Health Technol Assess 8, (9) iii-48 , DOI
(2004) 'Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite' Mult Scler 10, (1) 41-46 , DOI
(2004) 'Self-efficacy predicts self-reported health status in multiple sclerosis' Mult Scler 10, (1) 61-66 , DOI
(2004) 'Cannabis for dyskinesia in Parkinson disease - A randomized double-blind crossover study' Neurology 63, (7) 1245-1250
(2004) 'Capturing the true burden of dystonia on patients - The Cervical Dystonia Impact Profile (CDIP-58)' Neurology 63, (9) 1629-1633
(2004) 'Clinical trials in multiple sclerosis - The importance of the outcome measure' Journal of Neurology Neurosurgery and Psychiatry 75, (8)
(2004) 'Clinical trials in neurology: Are rating scales stable across European countries?' Journal of Neurology Neurosurgery and Psychiatry 75, (5)
(2004) 'Exploring rating scale responsiveness - Does the total score reflect the sum of its parts?' Neurology 62, (10) 1842-1844
(2004) 'Improving the evaluation of therapeutic interventions in multiple sclerosis: development of a patient-based measure of outcome' Health Technology Assessment 8, (9) 1-+
(2004) 'Measuring disability in multiple sclerosis: is the Community Dependency Index an improvement on the Barthel Index?' MULTIPLE SCLEROSIS JOURNAL 10, (4) 447-450 , DOI
(2004) 'Measuring disability in multiple sclerosis: is the Community Dependency Index an improvement on the Barthel Index?' Multiple Sclerosis 10, (4) 447-450
(2004) 'Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite' Multiple Sclerosis 10, (1) 41-46
(2004) 'Patient-based outcomes of cervical dystonia: A review of rating scales' Movement Disorders 19, (9) 1054-1059
(2004) 'Self-efficacy predicts self-reported health status in multiple sclerosis' Multiple Sclerosis 10, (1) 61-66
(2004) 'Stroke in Devon: knowledge was good, but action was poor' Journal of Neurology Neurosurgery and Psychiatry 75, (4) 567-571
(2004) 'The cervical dystonia impact profile (CDIP-58): A new patient-based rating scale' Journal of Neurology Neurosurgery and Psychiatry 75, (8)
(2004) 'The Leeds Multiple Sclerosis Quality of Life Scale: a further psychometric evaluation' Multiple Sclerosis 10, (7032) S99-S100
(2004) 'Cutting the cost and length of clinical trials - the importance of choosing the right outcome measure' Journal of Neurology 251, 152-153
(2003) 'Rating scales for neurologists' J Neurol Neurosurg Psychiatry 74 Suppl 4, (Suppl 4) iv22-iv26 , DOI
(2003) 'Rating scales for neurologists' JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY 74, 22-26
(2003) 'Socio-demographic variables are limited predictors of health status in multiple sclerosis' J Neurol 250, (9) 1088-1093 , DOI
(2003) 'A randomized controlled study of modified cobratoxin in adrenomyeloneuropathy' Neurology 61, (4) 528-530 , DOI
(2003) 'Evidence-based measurement in multiple sclerosis: the psychometric properties of the physical and psychological dimensions of three quality of life rating scales' Mult Scler 9, (4) 411-419 , DOI
(2003) 'Using the SF-36 measure to compare the health impact of multiple sclerosis and Parkinson's disease with normal population health profiles' J Neurol Neurosurg Psychiatry 74, (6) 710-714 , DOI
(2003) 'Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12)' Neurology 60, (1) 31-36 , DOI
(2003) 'Comparison of physician outcome measures and patients' perception of benefits of inpatient neurorehabilitation' Journal of Neurology Neurosurgery and Psychiatry 74, (8)
(2003) 'Evidence-based measurement in multiple sclerosis: the psychometric properties of the physical and psychological dimensions of three quality of life rating scales' Multiple Sclerosis 9, (4) 411-419
(2003) 'Measuring the impact of MS on walking ability - The 12-Item MS Walking Scale (MSWS-12)' Neurology 60, (1) 31-36
(2003) 'Rating scales for neurologists' Journal of Neurology Neurosurgery and Psychiatry 74, 22-26
(2003) 'Stroke in Devon: The need to translate knowledge into action' Journal of Neurology Neurosurgery and Psychiatry 74, (8)
(2003) 'Using the SF-36 measure to compare the health impact of multiple sclerosis and Parkinson's disease with normal population health profiles' Journal of Neurology Neurosurgery and Psychiatry 74, (6) 710-714
(2003) 'Socio-demographic variables are limited predictors of health status in multiple sclerosis' Journal of Neurology 250, (9) 1088-1093
(2002) 'Measuring disease impact in disabling neurological conditions: are patients' perspectives and scientific rigor compatible?' Curr Opin Neurol 15, (6) 721-724 , DOI
(2002) 'Multiple Sclerosis Impact Scale (MSIS-29): reliability and validity in hospital based samples' J Neurol Neurosurg Psychiatry 73, (6) 701-704 , DOI
(2002) 'Evaluating the use of B-INTERFERON in the UK: From whose perspective?' JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY 73, (2) 227-227
(2002) 'Comparison of physician outcome measures and patients' perception of benefits of inpatient neurorehabilitation' BMJ 324, (7352) , DOI
(2002) 'Quality of life measurement after stroke: uses and abuses of the SF-36' Stroke 33, (5) 1348-1356 , DOI
(2002) 'Use of the short form health survey (SF-36) in patients with amyotrophic lateral sclerosis: tests of data quality, score reliability, response rate and scaling assumptions' J Neurol 249, (2) 178-183 , DOI
(2002) 'Evaluating the use of B-INTERFERON in the UK: From whose perspective?' Journal of Neurology Neurosurgery and Psychiatry 73, (2) 227-227
(2002) 'Measuring disease impact in disabling neurological conditions: are patients' perspectives and scientific rigor compatible?' Current Opinion in Neurology 15, (6) 721-724
(2002) 'Multiple Sclerosis Impact Scale (MSIS-29): reliability and validity in hospital based samples' Journal of Neurology Neurosurgery and Psychiatry 73, (6) 701-704
(2002) 'Quality of life measurement after stroke - Uses and abuses of the SF-36' Stroke 33, (5) 1348-1356
(2002) 'Comparison of physician outcome measures and patients' perception of benefits of inpatient neurorehabilitation' British Medical Journal 324, (7352) 1493-1493
(2001) 'Evidence-based measurement: which disability scale for neurological rehabilitation?' Neurology 57, 639-644
(2001) 'The SF-36 in multiple sclerosis: why basic assumptions must be tested' Journal of Neurology, Neurosurgery and Psychiatry 71, (3) 363-370
(2001) 'The SF-36 in multiple sclerosis: why basic assumptions must be tested' J Neurol Neurosurg Psychiatry 71, (3) 363-370 , DOI
(2001) 'Does adding MS-specific items to a generic measure (the SF-36) improve measurement?' Neurology 57, (1) 68-74 , DOI
(2001) 'High dose naltrexone for dyskinesias induced by levodopa' J Neurol Neurosurg Psychiatry 70, (4) 554-556 , DOI
(2001) 'Evidence-based measurement: which disability scale for neurologic rehabilitation?' Neurology 57, 639-644
(2001) 'The multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure' Brain 124, (5) 962-973 , DOI
(2001) 'The multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure' Brain 124 (5), 962-973 , DOI
(2000) 'Kurtzke scales revisited: the application of psychometric methods to clinical intuition' Brain 123 ( Pt 5), 1027-1040 , DOI
(2000) 'Clinical appropriateness: a key factor in outcome measure selection: the 36 item short form health survey in multiple sclerosis' J Neurol Neurosurg Psychiatry 68, (2) 150-156 , DOI
(1999) 'Measuring change in disability after inpatient rehabilitation: comparison of the responsiveness of the Barthel index and the Functional Independence Measure' J Neurol Neurosurg Psychiatry 66, (4) 480-484 , DOI
(1999) 'Inpatient rehabilitation in multiple sclerosis: do the benefits carry over into the community?' Neurology 52, (1) 50-56 , DOI
(1998) '*The Impact of In-patient Rehabilitation on Disability and Handicap in Progressive Multiple Sclerosis: A randomised controlled trial' Physiotherapy 84, (8) 401-401 , DOI
(1998) 'Multiple sclerosis: assessment of disability and disability scales' J Neurol 245, (4) 189-196 , DOI
(1997) 'The impact of inpatient rehabilitation on progressive multiple sclerosis' Ann Neurol 42, (2) 236-244 , DOI
(1997) 'A comparison of two neurologic scoring instruments for multiple sclerosis' JOURNAL OF NEUROLOGY 244, (1) 60-60
(1996) 'Physician and patient-oriented outcomes in progressive neurological disease: which to measure?' Curr Opin Neurol 9, (6) 441-444 , DOI
(1996) 'Evaluating neurological outcome measures: The bare essentials' JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY 60, (2) 127-130 , DOI
(1996) 'Outcomes-based research in neurorehabilitation: the need for multidisciplinary team involvement' Disabil Rehabil 18, (2) 106-110 , DOI
(1996) 'Evaluating outcome measurement instruments' MS Management 1, (2) 6-12
(1996) 'Health-related quality of life in people with multiple sclerosis undergoing inpatient rehabilitation' JOURNAL OF NEUROLOGIC REHABILITATION 10, (3) 185-194
(1995) 'Reduced Disability Following Rehabilitation in Patients with Progressive Multiple Sclerosis' Physiotherapy 81, (8) 457-457 , DOI
(1995) 'Immediate and long term effects of inpatient rehabilitation in progressive multiple sclerosis (MS): Initial report' Journal of Neuroimmunology 56-63, 52-52 , DOI
(1990) 'A view from the other side' Health Services Journal 100(5230),
Reviews
(2006) 'Handbook of Neurological Rating Scales' Journal of Neurology,Neurosurgery and Psychiatry (77)
Chapters
(2011) 'Measuring quality of life in multiple system atrophy' Quality of Life Measurement in Neurodegenerative and Related Conditions Cambridge University Press 60-70 , DOI
(2011) 'Measuring quality of life in progressive supranuclear palsy' Quality of Life Measurement in Neurodegenerative and Related Conditions Cambridge University Press 52-59 , DOI
(2011) 'Rasch analysis' Quality of Life Measurement in Neurodegenerative and Related Conditions Cambridge University Press 147-164 , DOI
(2011) 'The Multiple Sclerosis Impact Scale (MSIS-29)' Quality of Life Measurement in Neurodegenerative and Related Conditions Cambridge University Press 24-40 , DOI
(2006) 'Measuring multiple sclerosis rehabilitation outcomes' Neurological Rehabilitation of Multiple Sclerosis CRC Press 109-135 , DOI
(2002) 'Measurement of neurological outcomes' Diseases of the Nervous System Cambridge University Press 105-117 , DOI
(2001) 'Assessment Measures and Clinical Scales' Clinical Trials in Neurology Springer London 17-28 , DOI
(1997) 'Clinical trials of multiple sclerosis' Interferon Therapy of Multiple Sclerosis 449-508
Conference Papers
(2022) 'Differences between clinical trials and "real-world" use of disease modifying therapies: insights from the UK OPTIMISE:MS pharmacovigilance study' 667-668
(2022) 'Predicting the risk of long-term relapse in MOGAD' 146-147
(2022) 'SARS-CoV-2 vaccination and COVID-19 infections in people with multiple sclerosis treated with ocrelizumab in the prospective, multicenter, noninterventional MuSicalE and CONFIDENCE studies' 518-520
(2022) 'The real-world effectiveness of ocrelizumab for treating patients with MS: 1-year data from the MuSicalE study' 635-635
(2022) 'COA DEVELOPMENT AND EVALUATION IN RARE DISEASE: A NARRATIVE REVIEW' S18-S18
(2021) 'Effect of Siponimod on the MSWS-12 and MSIS-29 in Patients With SPMS From the EXPAND Study' 359-359
(2021) 'Patient-reported Outcomes used in Multiple Sclerosis Trials: Critical Assessment and Insights from People Living with MS' 731-731
(2020) 'Cladribine to halt deterioration in people with advanced multiple sclerosis (CHARIOTMS)' 212-213
(2020) 'Hyperhidrosis Disease Severity Measure-Axillary: Evaluation of measurement properties in phase II study data' AB206-AB206
(2017) 'Maximizing brain health in multiple sclerosis: a quality improvement framework'
(2017) 'Prolonged-Release Fampridine Induces Sustained Clinically Meaningful Improvements in Walking Ability in People with Multiple Sclerosis: Results from the ENHANCE Trial'
(2015) 'Measuring the impact of multiple sclerosis: enhancing the MSIS-29's performance' 622-622
(2015) 'Suboptimal disability measurement in multiple sclerosis clinical trials: limitations of existing patient-reported outcomes measures' 341-341
(2015) 'Time matters in multiple sclerosis - international consensus recommendations on diagnosis, management and access to treatment' 801-802
(2015) 'Long-term efficacy and safety of prolonged-release fampridine treatment in patients with multiple sclerosis: design of the multicentre, randomised, double-blind, placebo-controlled ENHANCE study' 621-621
(2014) 'Identifying an important change threshold for the Multiple Sclerosis Walking Scale-12 (MSWS-12)' 410-411
(2012) 'A new path for the MS Walking Scale: MSWS-12 version 2' 334-335
(2012) 'Cannabis as a symptomatic treatment for MS: clinically meaningful MUSEC to the stiffness and walking problems of people with MS' 247-247
(2012) 'It's time to change the way we measure change: demonstration, explanation, recommendations' 32-32
(2012) 'Results from the Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial' in Hobart J; Wright D; Ball S; Nunn A; Vickery J ABN Annual Meeting Brighton 5-/-0/20125-/-0/2012
(2011) 'The timed 25-foot walk as an outcome measure for clinical trials in multiple sclerosis: further evidence that a 20% change is clinically meaningful' 150-150
(2010) 'RANKIN SCALES FOR MEASURING STROKE OUTCOMES: IS IT TIME TO THROW IN THE TOWEL?' E67-E67 , DOI
(2010) 'Beyond traditional psychometric methods: Can Rasch help the DASH?' 35-35
(2009) 'COMBINING SENSORY MODALITIES WITHIN A SENSORY SUM SCORE: ARE WE PICKING UP GOOD VIBRATIONS?' , DOI
(2009) 'RANDOMISED TRIAL OF METHOTREXATE IN CIDP STUDY: DID THE MEASUREMENT OF STRENGTH PROVE TO BE A WEAKNESS?' , DOI
(2009) 'COMBINING SENSORY MODALITIES WITHIN A SENSORY SUM SCORE: ARE WE PICKING UP GOOD VIBRATIONS?' 115-115
(2009) 'MAKING THE MOST OF ONLS DATA: CAN WE GET MORE OUT OF WHAT WE PUT IN?' 116-116
(2009) 'RANDOMISED TRIAL OF METHOTREXATE IN CIDP (RMC) STUDY: DID THE MEASUREMENT OF STRENGTH PROVE TO BE A WEAKNESS?' 116-117
(2008) 'Lessons from the Cannabinoids in Multiple Sclerosis (CAMS) Study: part 2-what happens when the Ashworth scale makes the grade2' S281-S282
(2008) 'Lessons front the Cannabinoids in Multiple Sclerosis (CAMS) Study : part 1-did Ashworth's scale make the grade?' S285-S285
(2008) 'Measuring upper limb functioning in multiple sclerosis: is the Disabilities of Arm, Shoulder and Hand (DASH) fit for purpose?' S279-S279
(2008) 'Is the ADAS-cog fit for purpose in clinical trials? Part 1 - basic measurement properties' 32-33
(2008) 'Is the ADAS-cog fit for purpose in clinical trials? Part 2 - examination by AD severity' 33-34
(2007) 'Measuring with rating scales - principles of measurements' S15-S15
(2007) 'Proxy measurements in MS: does patient's cognitive impairment influence patient-proxy agreement on disease impact?' S213-S213
(2007) 'Beware all neurologists: The FDA's tough new requirements for rating scale performance are coming to a study near you soon' 1031-1031
(2007) 'Rating scale responsiveness: Its time to change the way we measure change' 1035-1035
(2007) 'Sample size calculations for evaluating neurological rating scales: How many is enough?' 1026-1027
(2007) 'Selecting the right rating scale: Do neurologists have to have what they're given or can they get what they need?' 1034-1035
(2006) 'Longitudinal proxy measurements in multiple sclerosis: agreement between patients and their partners on the impact of MS on daily life over a period of two years' S86-S87
(2006) 'The multiple sclerosis impact scale is sensitive to factors predictive of increasing severity of multiple sclerosis' S87-S87
(2006) 'Does the GHQ-30 leave room for change?' 134-134
(2006) 'Getting the measure of spasticity in MS: The Multiple Sclerosis Spasticity Scale (MSSS-88)' 131-131
(2006) 'International co-operative ataxia rating scale (ICARS): Suitable for clinical practice and treatment trials in Friedreich's ataxia?' 133-133
(2006) 'Introducing the south west impact of multiple sclerosis (SWIMS) project: A population-based natural history project to acquire patient-orientated information about the impact of multiple sclerosis' 131-131
(2006) 'Is it Rasch to compare thee on another scale?' 133-133
(2006) 'Laughing all the way to the item bank: How to improve your treatment effect by improving your outcome measurement' 133-133
(2006) 'Meaningless statistics and the illusion of fatigue' 133-133
(2006) 'Rating scales for neurological diseases: Lessons from Rasch analysis' 137-137
(2006) 'The Friedreich's Ataxia impact scale (FAIS) meets the needs of today's clinical studies' 133-133
(2005) 'Confounding the confused: Is measuring the frequency and severity of cognitive impairment really necessary?' S220-S220
(2005) 'Developing rating scales for neurological diseases: Lessons from Rasch analysis' S229-S230
(2005) 'Getting the measure of spasticity in MS: The Multiple Sclerosis Spasticity Scale (MSSS-88)' S229-S229
(2005) 'Is it Rasch to compare thee on another scale?' S221-S221
(2005) 'Laughing all the way to the item bank: how to improve your treatment effect by improving your outcome measurement' S220-S221
(2005) 'CONFOUNDING THE CONFUSED: IS MEASURING THE FREQUENCY AND SEVERITY OF COGNITIVE IMPAIRMENT REALLY NECESSARY' 2013-2013
(2005) 'Confounding the confused: is measuring the frequency and severity of cognitive impairment really necessary?' S68-S68
(2005) 'Developing rating scales for multiple sclerosis: lessons from Rasch analysis' S104-S104
(2005) 'Getting the measure of spasticity in MS: the multiple sclerosis spasticity scale' S104-S104
(2005) 'Home or away? A randomised controlled trial of treating acute multiple sclerosis relapses with intravenous steroids' S181-S181
(2005) 'Introducing the South West Impact of Multiple Sclerosis Project: a patient-focused natural history study of multiple sclerosis' S110-S110
(2005) 'Is it Rasch to compare thee on another scale?' S104-S104
(2005) 'Meaningless statistics and the illusion of fatigue measurement' S68-S68
(2005) 'Proxy measurements in multiple sclerosis: agreement between patients and their partners on the impact of MS on daily life' S100-S100
(2004) 'The Leeds Multiple Sclerosis Quality of Life Scale: a further psychometric evaluation' S99-S100
(2004) 'Clinical trials in multiple sclerosis - The importance of the outcome measure' 1215-1215
(2004) 'The cervical dystonia impact profile (CDIP-58): A new patient-based rating scale' 1224-1224
(2004) 'Cutting the cost and length of clinical trials - the importance of choosing the right outcome measure' 152-153
(2004) 'Clinical trials in neurology: Are rating scales stable across European countries?' 801-801
(2003) 'Comparison of physician outcome measures and patients' perception of benefits of inpatient neurorehabilitation' 1182-1182
(2003) 'Stroke in Devon: The need to translate knowledge into action' 1176-1177
(1999) 'Use of clinical scales' 27-30
Presentations and posters
'Myths about rating scales: There is a magic number of response categories'
'Factors contributing to CSF NfL reduction over time in people with multiple sclerosis starting treatment: an observational study'
'Strengthening scale development for clinical practice: recommendations for the next decade'
'International consensus on quality standards for multiple sclerosis care: results from a modified Delphi process'
'036 Ocrelizumab real-world effectiveness in patients with relapsing and primary progressive multiple sclerosis: MuSicalE baseline data' , DOI
'18206 Hyperhidrosis Disease Severity Measure–Axillary: Evaluation of measurement properties in phase II study data' , DOI
'20 years of MSIS-29-importance of an MS specific QoL scale'
'Advancing walking measurement in multiple sclerosis clinical trials: a new patient-reported outcome measure'
'Alemtuzumab after Natalizumab SWitch in Evolving Rapidly Severe Multiple Sclerosis (ANSWERS MS)'
'Alemtuzumab after natalizumab SWitch in evolving rapidly severe multiple sclerosis (ANSWERS MS): long-term UK & Ireland experience'
'Alemtuzumab Outcomes Over 9 Years in RRMS Patients With Highly Active Disease From CARE-MS I and II (TOPAZ)'
'106 (NOT) comparing apples with apples; MS hospital episode statistics dashboard highlights variation in trusts’ reporting' , DOI
'107 The UK multiple sclerosis service and DMT prescribing audit of 70 centres: overview' , DOI
'108 UK multiple sclerosis service and DMT audit of 70 centres: variation in DMT prescribing' , DOI
'Assessment of treatment satisfaction in multiple sclerosis: a review of the literature'
'Baseline characteristics of patients enrolled in LEMQoL, a study assessing health-related quality of life in RRMS patients treated with alemtuzumab in a real-world clinical setting'
'110 UK multiple sclerosis service audit of 70 centres: MS-MDTs' , DOI
'111 UK Multiple Sclerosis service audit of 70 centres: caseloads, patient lists and databases' , DOI
'125 Towards an optimal multiple sclerosis patient case-load for a full-time MSologist' , DOI
'Brain health: time matters in multiple sclerosis - developmental process and objectives of international consensus policy recommendations'
'Clinical features of demyelination following anti-TNF alpha therapy'
'150 The 70 UK centre multiple sclerosis service and DMT prescribing audit: practical project solutions' , DOI
'152 AttackMS natalizumab for the treatment of people with inflammatory demyeli- nation suggestive of multiple sclerosis' , DOI
'153 ChariotMS – cladribine to halt deterioration in people with advanced multiple sclerosis (pwAMS)' , DOI
'Clinical outcomes assessment in MS trials: on balance, the Berg Balance Scale is a precarious measure'
'Design and rationale of the determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis (DELIVER-MS) trial'
'163 Development of clinical and patient-reported quality metrics for multiple sclerosis: a UK pilot study report' , DOI Open access
'176 Fingolimod associated immune haemolytic anaemia' , DOI
'Efficacy of prolonged-release fampridine vs placebo on walking ability, dynamic and static balance and quality-of-life: an integrated analysis of MOBILE and ENHANCE'
'Engaging Multiple Stakeholder Groups in the Development of Standards for Multiple Sclerosis Care: A Modified Delphi Process' Open access
'Expert consensus on standards for multiple sclerosis care: results from a modified Delphi process'
'Expert consensus on standards for multiple sclerosis care: results from a modified delphi process' , DOI
'Expert consensus on standards for multiple sclerosis care: Results from a modified Delphi process'
'Health-related quality of life improved in people with multiple sclerosis who had clinically meaningful changes in walking ability with PR-Fampridine: Post hoc analysis of enhance' , DOI
'Implementing quality recommendations in multiple sclerosis care - a strategic approach to improve brain health'
'Investigating referral patterns to Physiotherapy and Occupational Therapy: A clinical audit'
'Maximizing Brain Health in Multiple Sclerosis: A Quality Improvement Framework'
'Measuring treatment satisfaction in patients with RMS in the real world: is the TSQM fit for purpose? An evaluation using Teri-PRO study data'
'Measuring upper limb function in multiple sclerosis clinical trials: definition, conceptualisation and measurement' Open access
'Novel Assessment of Real-world Effectiveness of Ocrelizumab for Treatment of Patients with Relapsing and Primary Progressive Multiple Sclerosis: Design of a Multicenter Non-interventional Study (musicale Study)' , DOI
'Ocrelizumab treatment effect on upper limb function in PPMS patients with disability: subgroup results of the ORATORIO study to inform the ORATORIO-HAND study design'
'Ocrelizumab Treatment Effect on Upper Limb Function in PPMS Patients with Disability: Subgroup Results of the ORATORIO Study to Inform the ORATORIO-HAND Study Design'
'One-Year Interim Analysis of Health-Related Quality of Life in RRMS Patients Treated With Alemtuzumab in a Real-world Clinical Setting (LemQoL Study)'
'P550 Clinical features of demyelination following anti-TNFα therapy' , DOI
'PO132 Clinical features of demyelination following anti-tnfΑ therapy' , DOI
'POSA1 COA Development and Evaluation in Rare Disease: A Narrative Review' , DOI
'POSC2 A Case Study: Evaluation of the Infantile Neuroaxonal Dystrophy Rating Scale (INAD-RS)' , DOI
'Prolonged-release fampridine demonstrates rapid and sustained clinically meaningful improvements in walking ability over 24 weeks: MSWS-12 responders in the ENHANCE study'
'PWE-066 Clinical features of demyelination during anti-tnf therapy: preliminary outcomes of the pred4 study' , DOI
'Sustained clinically meaningful improvements in walking ability with prolonged-release fampridine: results from the placebo-controlled ENHANCE study'
'Time Matters in Multiple Sclerosis - International Consensus Recommendations on Diagnosis, Management and Treatment Access'
'Time Matters in Multiple Sclerosis - International Consensus Recommendations on Diagnosis, Management and Treatment Access'
'Time matters in multiple sclerosis international consensus recommendations on diagnosis, management, and treatment access'
'Time matters in multiple sclerosis-International consensus policy recommendations on diagnosis, management, and treatment access'
'The 10-Item Sickle Cell Disease Severity Measure (SCDSM-10): A Novel Measure of Daily SCD Symptom Severity Developed to Assess Benefit of GBT440, an Experimental HbS Polymerization Inhibitor' , DOI
'Timely intervention, monitoring and education MATTERS in multiple sclerosis (TIME MATTERS in MS): developing a globally applicable quality improvement tool'
'UK Multiple Sclerosis service audit of 70 centres: access to neuroradiology' , DOI
'Addressing the MS care paradox: practical solutions'
'Multiple sclerosis science: a unique opportunity to advance scientific developments and patient care'
'Patient-reported outcomes in multiple sclerosis clinical trials: Measurement lessons from the EXPAND study'
'Other Patient reported outcomes for MS studies - a successful marriage of scientific requirements and patient preference?'
'Measuring patient-reported upper limb function in multiple sclerosis clinical trials: Can item banks achieve measurement nirvana?'
'The UK multiple sclerosis care crisis: an audit of 70 services'
'Timely Intervention, Monitoring and Education MATTERS in MS (TIME MATTERS in MS): global applicability of the MS Brain Health quality improvement tool'
'Timely intervention, monitoring and education matters in ms (time matters in ms): global piloting of the ms brain health quality improvement tool'
'Factors contributing to CSF NfL reduction over time in people with multiple sclerosis starting treatment: an observational study'